- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02399683
Immune Modulation From Trichuris Trichiura
November 18, 2016 updated by: Christian Hvas, University of Aarhus
Mucosal and Systemic Immune Modulation From Trichuris Trichiura in a Self-infected Individual
Mucosal immunology during helminth infection
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The present study investigates the effects of Trichuris trichiura on human mucosal and systemic immunity in a single self-infected individual.
Study Type
Observational
Enrollment (Actual)
1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
A single healthy volunteer
Description
Inclusion Criteria:
- The included volunteer is a researcher within parasitology with main focus on Trichuris trichiura and Trichiura suis. He planned to infect himself and contacted our department with the purpose of being monitored during this infection for safety (medical supervision) and research reasons. The only clinical criterion for his inclusion in the study was that he was healthy.
Exclusion Criteria:
- N/A
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Trichuris trichiura eggs
One healthy volunteer
|
Live eggs from human whipworm, Trichuris trichiura
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Faecal egg excretion
Time Frame: 30 weeks
|
Weekly monitoring of fecal egg counts by microscopy
|
30 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mucosal T cell associated cytokines
Time Frame: Week 15
|
Biopsy sampling during established infection
|
Week 15
|
|
Systemic immune parameters (eosinophilia, Subtypes of circulating T cells)
Time Frame: 30 weeks
|
Weekly monitoring
|
30 weeks
|
|
Adverse events
Time Frame: 30 weeks
|
The included individual was monitored clinically every week for the development of diarrhea and weight loss, and by blood samples for anemia and inflammatory parameters every other week.
|
30 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jens F Dahlerup, MD, Aarhus University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (ACTUAL)
December 1, 2012
Study Completion (ACTUAL)
December 1, 2012
Study Registration Dates
First Submitted
March 12, 2015
First Submitted That Met QC Criteria
March 25, 2015
First Posted (ESTIMATE)
March 26, 2015
Study Record Updates
Last Update Posted (ESTIMATE)
November 21, 2016
Last Update Submitted That Met QC Criteria
November 18, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Trichuris trichiura
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
Turku University HospitalUniversity of TurkuRecruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn Disease in Remission | Crohn Disease of Small IntestineFinland
-
Tzaneio General HospitalRecruitingCrohn Disease (CD) | Crohn Disease of Ileum | Kono S Anastomosis | Extended Mesenteric ExcisionGreece
-
L2 Bio, LLCFDAMap; Akan Biosciences, Inc.Not yet recruitingCrohn&Amp;#39;s | Crohn&Amp;#39;s Disease (CD)
-
University Hospital, Clermont-FerrandNot yet recruiting
-
Central Hospital, Nancy, FranceNot yet recruitingCrohn Disease (CD)France
-
GLSMED Learning Health S.A.Not yet recruiting
-
University Hospital, Clermont-FerrandActive, not recruiting
-
University Hospital, GrenobleNot yet recruiting
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...RecruitingCrohn Disease (CD)France
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
Clinical Trials on Trichuris trichiura eggs
-
University of AarhusCompletedHelminthiasis | Helminth Infection
-
George Washington UniversityNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingTrichuriasis | Whipworm | Controlled Human InfectionUnited States
-
University of AarhusCompletedCrohn Disease | Ulcerative Colitis | Intestinal Helminthiasis
-
National Institute of Allergy and Infectious Diseases...Coronado Biosciences, Inc.; Autoimmunity Centers of ExcellenceTerminated
-
Ahmad Hussieny SalamaCompleted
-
Montefiore Medical CenterSimons FoundationCompleted
-
Mark LebwohlCoronado Biosciences, Inc.Completed
-
NYU Langone HealthCompletedUlcerative ColitisUnited States
-
Rigshospitalet, DenmarkUniversity of Copenhagen; Statens Serum Institut; Copenhagen University Hospital... and other collaboratorsCompletedRelapsing Multiple SclerosisDenmark
-
Charite University, Berlin, GermanyTerminatedMultiple SclerosisGermany